News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Concert Pharmaceuticals, Inc. (CNCE) Announces CTP-499 Late Breaking Presentation At The National Kidney Foundation 2014 Spring Clinical Meeting


3/19/2014 7:06:32 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that 48 week Phase 2 clinical results of CTP-499 in patients with diabetic kidney disease will be presented at the National Kidney Foundation 2014 Spring Clinical Meeting. The meeting will take place on April 22-26, 2014 at the MGM Grand in Las Vegas, NV. The podium presentation will be made by the lead author, Dr. Bhupinder Singh, a clinical investigator for the study at Southwest Clinical Research Institute, to present the clinical results during the Late Breaking Session on Friday, April 25, 2014, 9:30 am - 11:00 am PDT.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES